Return to search results.
Complete title: Feasibility of Implementing Pre-Transplant Evaluation by the Supportive Care Team for Patients Undergoing Hematopoietic Cell Transplantation for Hematological Malignancies
|Research Study Number||2659.00|
|Principal Investigator||Stephanie Lee, MD, MPH|
Research Study Description
Eligibility Criteria (must meet the following to participate in this study)
Genders Eligible for Study: Both
- Written informed consent
- English as primary language
- Planned autologous or allogeneic hematopoietic cell transplantation
- Presence of co-morbidities (hematopoietic cell transplant co-morbidity index [HCT-CI] score 3 or greater), high risk disease (relapse risk > 25%), or a planned type of transplant (human leukocyte antigen [HLA]-mismatched allogeneic or myeloablative) that places the patient at a higher than average risk of non-relapse mortality or relapse
Other eligibility criteria may apply.
Exclusions (conditions that would prevent participation in this study)
- First transplant of a planned tandem procedure (the second transplant is eligible)
Other exclusion criteria may apply.
Acute Lymphoid Leukemia (ALL); Hematologic Malignancies
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.